A Critical Assessment of Approaches to Improving the Efficiency of Cancer Clinical Trials
There are many reasons for focusing attention on the efficiency of clinical trials. First, improving the efficiency of clinical trials may expedite the finding of improved treatments. Developing an effective treatment may be a multistep process involving failures and partial successes along the way. Improving the efficiency of each component clinical trial expedites the entire process. The proliferation of new treatments derived from an improved understanding of tumor biology provides an additional inducement to improve the efficiency by which we screen and evaluate treatments. There are also often strong ethical motivations for conducting each clinical trial as efficiently as possible. If one treatment is more effective than the other, then certainly one wishes to expose as few patients as possible to the inferior treatment. If the treatments are of equivalent antitumor efficacy but the new experimental therapy is more toxic, as is often the case, then one would like to discard the new treatment as soon as possible. In addition to the opportunity cost and the ethical cost, there is also a monetary cost providing an incentive to improving efficiency.
KeywordsToxicity Tate Room 4B06 Tocol Ethi
Unable to display preview. Download preview PDF.
- Byar DP, Piantadosi S (1985) Factorial designs for randomized clinical trials. Cancer Treat Rep 10: 1055–1062Google Scholar
- Carter WH Jr, Wampler GL, Stablein DM (1983) Regression methods in the analysis of survival data in cancer combination chemotherapy. Dekker, New YorkGoogle Scholar
- Crowley J (1985) Discussion. Cancer Treat Rep 10: 1079–1080Google Scholar
- Ellenberg SS, Eisenberger MA (1985) An efficient design for phase-Ill studies of combination chemotherapies. Cancer Treat Rep 10: 1147–1152Google Scholar
- Peto R (1978) Clinical trial methodology. Biomedicine (Paris) 28: 24–36Google Scholar
- Simon R (1986) Confidence intervals for reporting clinical trial results. Ann Intern Med 105: 4429–4435Google Scholar
- Thall PF, Simon R, Ellenberg SS (1988 a) Optimal two-stage designs for clinical trials with binary response. Stat Med (in press)Google Scholar
- Thall PF, Simon R, Ellenberg SS (1988 b) A two-stage design for choosing among several experimental treatments and a control in phase-Ill clinical trials.Google Scholar
- Thall PF, Simon R, Ellenberg SS (1988 c) Two-stage selection and testing designs for comparative clinical trials. Biometrika (in press)Google Scholar